|
1
|
Macdonald JS, Smalley SR, Benedetti J,
Hundahl SA, Estes NC, Stemmermann GN, Haller DG, Ajani JA,
Gunderson LL, Jessup JM and Martenson JA: Chemoradiotherapy after
surgery compared with surgery alone for adenocarcinoma of the
stomach or gastroesophageal junction. N Engl J Med. 345:725–730.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Seeruttun SR, Yuan S, Qiu H, Huang Y, Li
Y, Liang Y, Guan Y, Zhan Y, Li W, Chen Y, et al: A comprehensive
analysis comparing the eighth AJCC gastric cancer pathological
classification to the seventh, sixth, and fifth editions. Cancer
Med. 6:2804–2813. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Sakuramoto S, Sasako M, Yamaguchi T,
Kinoshita T, Fujii M, Nashimoto A, Furukawa H, Nakajima T, Ohashi
Y, Imamura H, et al: Adjuvant chemotherapy for gastric cancer with
S-1, an oral fluoropyrimidine. N Engl J Med. 357:1810–1820. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Bang YJ, Kim YW, Yang HK, Chung HC, Park
YK, Lee KH, Lee KW, Kim YH, Noh SI, Cho JY, et al: Adjuvant
capecitabine and oxaliplatin for gastric cancer after D2
gastrectomy (CLASSIC): A phase 3 open-label, randomised controlled
trial. Lancet. 379:315–321. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Japanese Gastric Cancer Association, .
Japanese gastric cancer treatment guidelines 2014 (ver. 4). Gastric
Cancer. 20:1–19. 2017. View Article : Google Scholar
|
|
6
|
Smyth EC, Verheij M, Allum W, Cunningham
D, Cervantes A and Arnold D; ESMO Guidelines Committee, : Gastric
cancer: ESMO clinical practice guidelines for diagnosis, treatment
and follow-up. Ann Oncol. 27 (Suppl 5):v38S–v49S. 2016. View Article : Google Scholar
|
|
7
|
Ajani JA, D'Amico TA, Baggstrom M, et al:
Gastric cancer, version 5.2017. NCCN Clinical Practice Guidelines
in Oncology. 14:1286–1312. 2017.
|
|
8
|
Wang FH, Shen L, Li J, Zhou ZW, Liang H,
Zhang XT, Tang L, Xin Y, Jin J, Zhang YJ, et al: The chinese
society of clinical oncology (CSCO): Clinical guidelines for the
diagnosis and treatment of gastric cancer. Cancer Commun (Lond).
39:102019. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Smalley SR, Benedetti JK, Haller DG,
Hundahl SA, Estes NC, Ajani JA, Gunderson LL, Goldman B, Martenson
JA, Jessup JM, et al: Updated analysis of SWOG-directed intergroup
study 0116: A phase III trial of adjuvant radiochemotherapy versus
observation after curative gastric cancer resection. J Clin Oncol.
30:2327–2333. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Hundahl SA, Macdonald JS, Benedetti J and
Fitzsimmons T; Southwest Oncology Group and the Gastric Intergroup,
: Surgical treatment variation in a prospective, randomized trial
of chemoradiotherapy in gastric cancer: The effect of
undertreatment. Ann Surg Oncol. 9:278–286. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Choi KH and Kim BS, Oh ST, Yook JH and Kim
BS: Comparison the sixth and seventh editions of the AJCC staging
system for T1 gastric cancer: A long-term follow-up study of 2124
patients. Gastric Cancer. 20:43–48. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Lee J, Lim DH, Kim S, Park SH, Park JO,
Park YS, Lim HY, Choi MG, Sohn TS, Noh JH, et al: Phase III trial
comparing capecitabine plus cisplatin versus capecitabine plus
cisplatin with concurrent capecitabine radiotherapy in completely
resected gastric cancer with D2 lymph node dissection: The ARTIST
trial. J Clin Oncol. 30:268–273. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Park SH, Sohn TS, Lee J, Lim DH, Hong ME,
Kim KM, Sohn I, Jung SH, Choi MG, Lee JH, et al: Phase III trial to
compare adjuvant chemotherapy with capecitabine and cisplatin
versus concurrent chemoradiotherapy in gastric cancer: Final report
of the adjuvant chemoradiotherapy in stomach tumors trial,
including survival and subset analyses. J Clin Oncol. 33:3130–3136.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Kim Y, Kim KM, Choi MG, Lee JH, Sohn TS,
Bae JM, Kim S, Lee SJ, Kim ST, Lee J, et al: Adjuvant chemotherapy
with or without concurrent radiotherapy for patients with stage IB
gastric cancer: A subgroup analysis of the adjuvant
chemoradiotherapy in stomach tumors (ARTIST) phase III trial. J
Gastric Cancer. 18:348–355. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Coburn NG, Govindarajan A, Law CH, Guller
U, Kiss A, Ringash J, Swallow CJ and Baxter NN: Stage-specific
effect of adjuvant therapy following gastric cancer resection: A
population-based analysis of 4,041 patients. Ann Surg Oncol.
15:500–507. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Japanese Gastric Cancer Association, .
Japanese classification of gastric carcinoma-2nd english edition.
Gastric Cancer. 1:10–24. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Sasako M, Sakuramoto S, Katai H, Kinoshita
T, Furukawa H, Yamaguchi T, Nashimoto A, Fujii M, Nakajima T and
Ohashi Y: Five-year outcomes of a randomized phase III trial
comparing adjuvant chemotherapy with S-1 versus surgery alone in
stage II or III gastric cancer. J Clin Oncol. 29:4387–4393. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Noh SH, Park SR, Yang HK, Chung HC, Chung
IJ, Kim SW, Kim HH, Choi JH, Kim HK, Yu W, et al: Adjuvant
capecitabine plus oxaliplatin for gastric cancer after D2
gastrectomy (CLASSIC): 5-year follow-up of an open-label,
randomised phase 3 trial. Lancet Oncol. 15:1389–1396. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
GASTRIC (Global Advanced/Adjuvant Stomach
Tumor Research International Collaboration) Group, ; Paoletti X,
Oba K, Burzykowski T, Michiels S, Ohashi Y, Pignon JP, Rougier P,
Sakamoto J, Sargent D, et al: Benefit of adjuvant chemotherapy for
resectable gastric cancer: A meta-analysis. JAMA. 303:1729–1737.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Dudeja V, Habermann EB, Abraham A, Zhong
W, Parsons HM, Tseng JF and Al-Refaie WB: Is there a role for
surgery with adequate nodal evaluation alone in gastric
adenocarcinoma? J Gastrointest Surg. 16:238–247. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Seyedin S, Wang PC, Zhang Q and Lee P:
Benefit of adjuvant chemoradiotherapy for gastric adenocarcinoma: A
SEER population analysis. Gastrointest Cancer Res. 7:82–90.
2014.PubMed/NCBI
|
|
22
|
Datta J, McMillan MT, Ruffolo L, Lowenfeld
L, Mamtani R, Plastaras JP, Dempsey DT, Karakousis GC, Drebin JA,
Fraker DL and Roses RE: Multimodality therapy improves survival in
resected early stage gastric cancer in the United States. Ann Surg
Oncol. 23:2936–2945. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Wang Z, Yan J, Hu W, Zhang J and Huo B:
Adjuvant chemotherapy provided survival benefit for stage T2N0
gastric cancer with high-risk factors. Neoplasma. 65:592–598. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Du C, Zhou Y, Huang K, Zhao G, Fu H and
Shi Y: Defining a high-risk subgroup of pathological T2N0 gastric
cancer by prognostic risk stratification for adjuvant therapy. J
Gastrointest Surg. 15:2153–2158. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Park JH, Ryu MH, Kim HJ, Ryoo BY, Yoo C,
Park I, Park YS, Oh ST, Yook JH, Kim BS and Kang YK: Risk factors
for selection of patients at high risk of recurrence or death after
complete surgical resection in stage I gastric cancer. Gastric
Cancer. 19:226–233. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Hwang JE, Hong JY, Kim JE, Shim HJ, Bae
WK, Hwang EC, Jeong O, Park YK, Lee KH, Lee JH, et al: Prognostic
significance of the concomitant existence of lymphovascular and
perineural invasion in locally advanced gastric cancer patients who
underwent curative gastrectomy and adjuvant chemotherapy. Jpn J
Clin Oncol. 45:541–546. 2015.PubMed/NCBI
|
|
27
|
Araki I, Hosoda K, Yamashita K, Katada N,
Sakuramoto S, Moriya H, Mieno H, Ema A, Kikuchi S, Mikami T and
Watanabe M: Prognostic impact of venous invasion in stage IB
node-negative gastric cancer. Gastric Cancer. 18:297–305. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Yokoyama T, Kamada K, Tsurui Y, Kashizuka
H, Okano E, Ogawa S, Obara S and Tatsumi M: Clinicopathological
analysis for recurrence of stage Ib gastric cancer (according to
the second english edition of the Japanese classification of
gastric carcinoma). Gastric Cancer. 14:372–377. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Ohtsu A and Sasako M: Overview of adjuvant
therapy for resected gastric cancer: Differences in Japan and the
United States. Semin Oncol. 32 (6 Suppl 9):S101–S104. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Wang Y, Zhang J, Guo S, Dong Z, Meng X,
Zheng G, Yang D, Zheng Z and Zhao Y: Implication of lymph node
staging in migration and different treatment strategies for stage
T2N0M0 and T1N1M0 resected gastric cancer: A SEER population
analysis. Clin Transl Oncol. 21:1499–1509. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
In H, Kantor O, Sharpe SM, Baker MS,
Talamonti MS and Posner MC: Adjuvant therapy improves survival for
T2N0 gastric cancer patients with sub-optimal lymphadenectomy. Ann
Surg Oncol. 23:1956–1962. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Aoyama T, Yoshikawa T, Fujikawa H, Hayashi
T, Ogata T, Cho H, Yamada T, Hasegawa S, Tsuchida K, Yukawa N, et
al: Prognostic factors in stage IB gastric cancer. World J
Gastroenterol. 20:6580–6585. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Sunakawa Y and Lenz HJ: Molecular
classification of gastric adenocarcinoma: Translating new insights
from the cancer genome atlas research network. Curr Treat Options
Oncol. 16:172015. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Polom K, Marano L, Marrelli D, De Luca R,
Roviello G, Savelli V, Tan P and Roviello F: Meta-analysis of
microsatellite instability in relation to clinicopathological
characteristics and overall survival in gastric cancer. Br J Surg.
105:159–167. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Choi YY, Kim H, Shin SJ, Kim HY, Lee J,
Yang HK, Kim WH, Kim YW, Kook MC, Park YK, et al: Microsatellite
instability and programmed cell death-ligand 1 expression in stage
II/III gastric cancer: Post hoc analysis of the CLASSIC randomized
controlled study. Ann Surg. 270:309–316. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Miceli R, An J, Di Bartolomeo M, Morano F,
Kim ST, Park SH, Choi MG, Lee JH, Raimondi A, Fucà G, et al:
Prognostic impact of microsatellite instability in asian gastric
cancer patients enrolled in the ARTIST trial. Oncology. 97:38–43.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Dai D, Zhao X, Li X, Shu Y, Shen B, Chen
X, Chen D and Wang D: Association between the microsatellite
instability status and the efficacy of postoperative adjuvant
chemoradiotherapy in patients with gastric cancer. Front Oncol.
9:14522020. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Lordick F: Chemotherapy for resectable
microsatellite instability-high gastric cancer? Lancet Oncol.
21:2032020. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Van't Veer LJ, Dai H, van de Vijver MJ, He
YD, Hart AA, Mao M, Peterse HL, van der Kooy K, Marton MJ,
Witteveen AT, et al: Gene expression profiling predicts clinical
outcome of breast cancer. Nature. 415:530–536. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Nakamura K, Hatakeyama K, Furukawa K,
Fujiya K, Kamiya S, Hikage M, Tanizawa Y, Bando E, Ohshima K,
Urakami K, et al: Prediction of S-1 adjuvant chemotherapy benefit
in stage II/III gastric cancer treatment based on comprehensive
gene expression analysis. Gastric Cancer. 23:648–658. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Cheong JH, Yang HK, Kim H, Kim WH, Kim YW,
Kook MC, Park YK, Kim HH, Lee HS, Lee KH, et al: Predictive test
for chemotherapy response in resectable gastric cancer: A
multi-cohort, retrospective analysis. Lancet Oncol. 19:629–638.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Roskoski R Jr: The ErbB/HER family of
protein-tyrosine kinases and cancer. Pharmacol Res. 79:34–74. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Begnami MD, Fukuda E, Fregnani JH,
Nonogaki S, Montagnini AL, da Costa WL Jr and Soares FA: Prognostic
implications of altered human epidermal growth factor receptors
(HERs) in gastric carcinomas: HER2 and HER3 are predictors of poor
outcome. J Clin Oncol. 29:3030–3036. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Wang S, Zheng G, Chen L and Xiong B:
Effect of HER-2/neu over-expression on prognosis in gastric cancer:
A meta-analysis. Asian Pac J Cancer Prev. 12:1417–1423.
2011.PubMed/NCBI
|
